Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 7 (2010), Issue 8 (August)

1. Cannula placement for effective convection-enhanced delivery in the nonhuman primate thalamus and brainstem: implications for clinical delivery of therapeutics.
   J Neurosurg, 113(2): 240-8. [Abstract] [Full-text]
2. Poor drug distribution as a possible explanation for the results of the PRECISE trial.
   J Neurosurg, 113(2): 301-9. [Abstract] [Full-text]
3. A thermal gel depot for local delivery of paclitaxel to treat experimental brain tumors in rats.
   J Neurosurg, 113(2): 210-7. [Abstract] [Full-text]
4. Increased depressive behaviour in mice harboring the mutant thyroid hormone receptor alpha 1.
   Behav Brain Res, 214(2): 187-92. [Abstract] [Full-text]
5. Increased depressive behaviour in mice harboring the mutant thyroid hormone receptor alpha 1.
   Behav Brain Res, 214(2): 187-92. [Abstract] [Full-text]
6. Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study.
   Br J Ophthalmol, 94(8): 1045-51. [Abstract] [Full-text]
7. Development of a sustained fluoride delivery system.
   Angle Orthod, 80(6): 1129-35. [Abstract] [Full-text]
8. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma.
   J Natl Cancer Inst, 102(15): 1188-98. [Abstract] [Full-text]
9. Photodynamic therapy with verteporfin for symptomatic circumscribed choroidal hemangioma: five-year outcomes.
   Ophthalmology, 117(8): 1630-7. [Abstract] [Full-text]
10. Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery).
    Ophthalmology, 117(8): 1623-9. [Abstract] [Full-text]
11. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
    Cochrane Database Syst Rev, 8: CD007477. [Abstract] [Full-text]
12. Availability and use of essential medicines in China: manufacturing, supply, and prescribing in Shandong and Gansu provinces.
    BMC Health Serv Res, 10: 211. [Abstract] [Full-text]
13. Autoimmune diabetes in HIV-infected patients on highly active antiretroviral therapy.
    J Clin Endocrinol Metab, 95(8): 4056-60. [Abstract] [Full-text]
14. Successful treatment of late, recurrent wilms tumor with high-dose chemotherapy and autologous stem cell rescue in third complete response.
    J Pediatr Hematol Oncol, 32(6): e241-3. [Abstract] [Full-text]
15. Isolated gut relapse presenting as chronic diarrhea during maintenance therapy for acute lymphoblastic leukemia.
    J Pediatr Hematol Oncol, 32(6): 504-5. [Abstract] [Full-text]
16. Sorafenib plus valproic acid for infant spinal glioblastoma.
    J Pediatr Hematol Oncol, 32(6): 511-4. [Abstract] [Full-text]
17. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 116(5): 679-86. [Abstract] [Full-text]
18. A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149).
    Gynecol Oncol, 118(3): 308-12. [Abstract] [Full-text]
19. A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Gynecol Oncol, 118(3): 303-7. [Abstract] [Full-text]
20. Spectrum of cancer risk late after AIDS onset in the United States.
    Arch Intern Med, 170(15): 1337-45. [Abstract] [Full-text]
21. Preventing potentially inappropriate medication use in hospitalized older patients with a computerized provider order entry warning system.
    Arch Intern Med, 170(15): 1331-6. [Abstract] [Full-text]
22. Impact of Medicare Part D on seniors' out-of-pocket expenditures on medications.
    Arch Intern Med, 170(15): 1325-30. [Abstract] [Full-text]
23. Ambulatory antibiotic use and prescription drug coverage in older adults.
    Arch Intern Med, 170(15): 1308-14. [Abstract] [Full-text]
24. UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.
    Br J Cancer, 103(4): 581-9. [Abstract] [Full-text]
25. Hormone replacement therapy and incidence of central nervous system tumours in the Million Women Study.
    Int J Cancer, 127(7): 1692-8. [Abstract] [Full-text]
26. Hormonal replacement therapy may reduce the risk for RA in women with early arthritis who carry HLA-DRB1 *01 and/or *04 alleles by protecting against the production of anti-CCP: results from the ESPOIR cohort.
    Ann Rheum Dis, 69(9): 1683-6. [Abstract] [Full-text]
27. Outcome of antibiotic prophylaxis discontinuation in patients with persistent vesicoureteral reflux initially presenting with febrile urinary tract infection: time to event analysis.
    J Urol, 184(3): 1093-8. [Abstract] [Full-text]
28. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial.
    Blood, 116(6): 971-8. [Abstract] [Full-text]
29. A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer.
    Cancer Chemother Pharmacol, 66(5): 987-92. [Abstract] [Full-text]
30. The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.
    Cancer Chemother Pharmacol, 66(5): 973-80. [Abstract] [Full-text]
31. Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors.
    Cancer Chemother Pharmacol, 66(5): 927-33. [Abstract] [Full-text]
32. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo.
    Cancer Chemother Pharmacol, 66(5): 869-80. [Abstract] [Full-text]
33. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol, 66(5): 889-97. [Abstract] [Full-text]
34. Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer.
    Cancer Chemother Pharmacol, 66(5): 913-8. [Abstract] [Full-text]
35. Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.
    Cancer Chemother Pharmacol, 66(5): 899-911. [Abstract] [Full-text]
36. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo.
    Cancer Chemother Pharmacol, 66(5): 881-8. [Abstract] [Full-text]
37. A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer.
    Cancer Chemother Pharmacol, 66(5): 861-8. [Abstract] [Full-text]
38. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study.
    Cancer Chemother Pharmacol, 66(5): 837-44. [Abstract] [Full-text]
39. A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer.
    Cancer Chemother Pharmacol, 66(5): 829-35. [Abstract] [Full-text]
40. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.
    Lancet, 376(9740): 532-9. [Abstract] [Full-text]
41. Concurrent liposomal cisplatin (Lipoplatin), 5-fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: a phase I/II study.
    Int J Radiat Oncol Biol Phys, 78(1): 150-5. [Abstract] [Full-text]
42. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
    Int J Radiat Oncol Biol Phys, 78(1): 85-90. [Abstract] [Full-text]
43. Development of nitrosyl ruthenium complex-loaded lipid carriers for topical administration: improvement in skin stability and in nitric oxide release by visible light irradiation.
    J Pharm Biomed Anal, 53(4): 843-51. [Abstract] [Full-text]
44. Development of nitrosyl ruthenium complex-loaded lipid carriers for topical administration: improvement in skin stability and in nitric oxide release by visible light irradiation.
    J Pharm Biomed Anal, 53(4): 843-51. [Abstract] [Full-text]
45. Development of nitrosyl ruthenium complex-loaded lipid carriers for topical administration: improvement in skin stability and in nitric oxide release by visible light irradiation.
    J Pharm Biomed Anal, 53(4): 843-51. [Abstract] [Full-text]
46. The central serotonin 2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity.
    J Neurochem, 114(5): 1323-32. [Abstract] [Full-text]
47. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.
    J Natl Cancer Inst, 102(16): 1253-62. [Abstract] [Full-text]
48. Dealing with sparse data in predicting outcomes of HIV combination therapies.
    Bioinformatics, 26(17): 2085-92. [Abstract] [Full-text]
49. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
    J Clin Oncol, 28(24): 3890-8. [Abstract] [Full-text]
50. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.
    J Clin Oncol, 28(24): 3880-9. [Abstract] [Full-text]
51. Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use.
    J Clin Oncol, 28(24): 3830-7. [Abstract] [Full-text]
52. Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia.
    J Clin Oncol, 28(24): 3816-23. [Abstract] [Full-text]
53. Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy.
    J Clin Oncol, 28(24): 3872-9. [Abstract] [Full-text]
54. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.
    J Clin Oncol, 28(24): 3851-7. [Abstract] [Full-text]
55. Do patients with structural abnormalities of the shoulder experience pain after MR arthrography of the shoulder?
    Radiology, 256(3): 870-8. [Abstract] [Full-text]
56. Reconstitution of CD4 T cells in bronchoalveolar lavage fluid after initiation of highly active antiretroviral therapy.
    J Virol, 84(18): 9010-8. [Abstract] [Full-text]
57. Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.
    J Virol, 84(18): 9632-6. [Abstract] [Full-text]
58. The extent of injection site infection in injecting drug users: findings from a national surveillance study.
    Epidemiol Infect, 138(10): 1510-8. [Abstract] [Full-text]
59. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR.
    Lancet Neurol, 9(9): 866-74. [Abstract] [Full-text]
60. Purkinje cells from RyR2 mutant mice are highly arrhythmogenic but responsive to targeted therapy.
    Circ Res, 107(4): 512-9. [Abstract] [Full-text]
61. Changing paradigms in surgical resuscitation.
    Crit Care Med, 38(9): S411-20. [Abstract] [Full-text]
62. The passive leg-raising maneuver cannot accurately predict fluid responsiveness in patients with intra-abdominal hypertension.
    Crit Care Med, 38(9): 1824-9. [Abstract] [Full-text]
63. Systematic review of physical and chemical compatibility of commonly used medications administered by continuous infusion in intensive care units.
    Crit Care Med, 38(9): 1890-8. [Abstract] [Full-text]
64. Cellular and molecular mechanisms of photodynamic hypericin therapy for nasopharyngeal carcinoma cells.
    J Pharmacol Exp Ther, 334(3): 847-53. [Abstract] [Full-text]
65. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study.
    Blood, 116(7): 1092-104. [Abstract] [Full-text]
66. Accuracy of the glenohumeral injection using the superior approach: a cadaveric study of injection accuracy.
    Am J Phys Med Rehabil, 89(9): 755-8. [Abstract] [Full-text]
67. Digital subtraction angiography-guided percutaneous sclerotherapy of venous malformations with pingyangmycin and/or absolute ethanol in the maxillofacial region.
    J Oral Maxillofac Surg, 68(9): 2258-66. [Abstract] [Full-text]
68. Lycopene phytocomplex, but not pure lycopene, is able to trigger apoptosis and improve the efficacy of photodynamic therapy in HL60 human leukemia cells.
    Exp Biol Med (Maywood), 235(9): 1114-25. [Abstract] [Full-text]
69. A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma.
    Ann Hematol, 89(10): 1019-27. [Abstract] [Full-text]
70. Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy.
    Ann Hematol, 89(10): 985-91. [Abstract] [Full-text]
71. Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy.
    Br J Cancer, 103(5): 656-62. [Abstract] [Full-text]
72. Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.
    Br J Cancer, 103(5): 622-8. [Abstract] [Full-text]
73. Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study.
    J Acquir Immune Defic Syndr, 55(1): 117-27. [Abstract] [Full-text]
74. Hospitalizations for invasive pneumococcal disease among HIV-1-infected adolescents and adults in the United States in the era of highly active antiretroviral therapy and the conjugate pneumococcal vaccine.
    J Acquir Immune Defic Syndr, 55(1): 128-31. [Abstract] [Full-text]
75. Retrospective study on the critical factors for retaining patients on antiretroviral therapy in KwaZulu-Natal, South Africa.
    J Acquir Immune Defic Syndr, 55(1): 109-16. [Abstract] [Full-text]
76. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.
    J Acquir Immune Defic Syndr, 55(1): 39-48. [Abstract] [Full-text]
77. Committee opinion no. 465: antimicrobial prophylaxis for cesarean delivery: timing of administration.
    Obstet Gynecol, 116(3): 791-2. [Abstract] [Full-text]
78. Incidence and predictors of postoperative deep vein thrombosis in cardiac surgery in the era of aggressive thromboprophylaxis.
    Ann Thorac Surg, 90(3): 760-6; discussion 766-8. [Abstract] [Full-text]
79. Intracellular localisation, geno- and cytotoxic response of polyN-isopropylacrylamide (PNIPAM) nanoparticles to human keratinocyte (HaCaT) and colon cells (SW 480).
    Toxicol Lett, 198(2): 134-43. [Abstract] [Full-text]
80. Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain.
    Proc Natl Acad Sci U S A, 107(34): 15205-10. [Abstract] [Full-text]
81. Progress in cancer chemotherapy with special stress on molecular-targeted therapy.
    Jpn J Clin Oncol, 40(9): 855-62. [Abstract] [Full-text]
82. Do children infected with HIV receiving HAART need to be revaccinated?
    Lancet Infect Dis, 10(9): 630-42. [Abstract] [Full-text]
83. Increasing damage to tumor blood vessels during motexafin lutetium-PDT through use of low fluence rate.
    Radiat Res, 174(3): 331-40. [Abstract] [Full-text]
84. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.
    Blood, 116(8): 1220-7. [Abstract] [Full-text]
85. Discontinuation of hormone therapy in the French GAZEL cohort 1990-2006.
    Fertil Steril, 94(4): 1387-91. [Abstract] [Full-text]
86. Impact of chemotherapeutics and advanced testicular cancer or Hodgkin lymphoma on sperm deoxyribonucleic acid integrity.
    Fertil Steril, 94(4): 1374-9. [Abstract] [Full-text]
87. Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells?
    Cell Mol Life Sci, 67(18): 3115-30. [Abstract] [Full-text]
88. Incidence of side effects using carbon dioxide-oxygen foam for chemical ablation of superficial veins of the lower extremity.
    Eur J Vasc Endovasc Surg, 40(3): 407-13. [Abstract] [Full-text]
89. Ultrasound guided foam sclerotherapy: factors associated with outcomes and complications.
    Eur J Vasc Endovasc Surg, 40(3): 389-92. [Abstract] [Full-text]
90. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.
    Int J Cancer, 127(8): 1941-7. [Abstract] [Full-text]
91. Action of estrogens in the aging brain: dementia and cognitive aging.
    Biochim Biophys Acta, 1800(10): 1077-83. [Abstract] [Full-text]
92. A case of angioimmunoblastic T-cell non-Hodgkin lymphoma with a neocentric inv dup(1).
    Cancer Genet Cytogenet, 202(1): 38-42. [Abstract] [Full-text]
93. Continuous glucose monitoring-enabled insulin-pump therapy in diabetic pregnancy.
    Acta Obstet Gynecol Scand, 89(9): 1233-7. [Abstract] [Full-text]
94. Stroke thrombolysis: having more time translates into delayed therapy: data from the Austrian Stroke Unit Registry.
    Stroke, 41(9): 2001-4. [Abstract] [Full-text]
95. Endovascular treatment of acute ischemic stroke may be safely performed with no time window limit in appropriately selected patients.
    Stroke, 41(9): 1996-2000. [Abstract] [Full-text]
96. A computerized in-hospital alert system for thrombolysis in acute stroke.
    Stroke, 41(9): 1978-83. [Abstract] [Full-text]
97. Current practice versus willingness to enroll in clinical trials: paradox among vascular neurologists about treatment for acute ischemic stroke.
    Stroke, 41(9): 2038-43. [Abstract] [Full-text]
98. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS).
    Stroke, 41(9): 1984-9. [Abstract] [Full-text]
99. Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study.
    Pediatr Blood Cancer, 55(4): 629-38. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.